ALR Technologies Completes Definitive Manufacturing Agreement for GluCurve Pet CGM
ALR Technologies (OTCPK:ALRTF) has secured a Definitive Manufacturing Agreement with CGM Medical Technology Shen Zhen for the production of Continuous Glucose Monitor (CGM) hardware for its GluCurve Pet CGM system. The agreement grants ALRT exclusive global distribution rights in the animal health market.
The first commercial shipment is expected in Q3 2025. ALRT plans to establish a joint venture with CGM Medical to build an automated manufacturing facility in Singapore, pending successful sample testing and production thresholds. The company aims to expand its presence in both human and animal health diabetes markets, with potential investment and commercial opportunities under consideration.
ALR Technologies (OTCPK:ALRTF) ha siglato un Accordo Definitivo di Produzione con CGM Medical Technology Shen Zhen per la realizzazione dell'hardware del Monitor Continuo del Glucosio (CGM) destinato al suo sistema GluCurve Pet CGM. L'accordo conferisce ad ALRT i diritti esclusivi di distribuzione globale nel mercato della salute animale.
La prima spedizione commerciale è prevista per il terzo trimestre 2025. ALRT intende costituire una joint venture con CGM Medical per realizzare un impianto di produzione automatizzato a Singapore, soggetto al superamento dei test sui campioni e delle soglie produttive. L'azienda mira a espandere la propria presenza nei mercati del diabete sia umano che animale, valutando potenziali investimenti e opportunità commerciali.
ALR Technologies (OTCPK:ALRTF) ha asegurado un Acuerdo Definitivo de Fabricación con CGM Medical Technology Shen Zhen para la producción del hardware del Monitor Continuo de Glucosa (CGM) para su sistema GluCurve Pet CGM. El acuerdo otorga a ALRT derechos exclusivos de distribución global en el mercado de salud animal.
El primer envío comercial está previsto para el tercer trimestre de 2025. ALRT planea establecer una empresa conjunta con CGM Medical para construir una planta de fabricación automatizada en Singapur, condicionada al éxito en las pruebas de muestras y los umbrales de producción. La compañía busca ampliar su presencia en los mercados de diabetes tanto humana como animal, considerando posibles inversiones y oportunidades comerciales.
ALR Technologies (OTCPK:ALRTF)는 CGM Medical Technology Shen Zhen과 글루커브 펫 CGM 시스템용 연속 혈당 측정기(CGM) 하드웨어 생산에 관한 확정 제조 계약을 체결했습니다. 이 계약을 통해 ALRT는 동물 건강 시장에서 전 세계 독점 유통 권리를 확보했습니다.
첫 상업적 출하는 2025년 3분기에 예정되어 있습니다. ALRT는 샘플 테스트와 생산 기준을 성공적으로 통과할 경우, CGM Medical과 합작 투자로 싱가포르에 자동화 제조 시설을 설립할 계획입니다. 회사는 인간과 동물 건강 당뇨 시장 모두에서 입지를 확대하고자 하며, 투자 및 상업적 기회도 검토 중입니다.
ALR Technologies (OTCPK:ALRTF) a conclu un accord définitif de fabrication avec CGM Medical Technology Shen Zhen pour la production du matériel du moniteur continu de glucose (CGM) pour son système GluCurve Pet CGM. Cet accord confère à ALRT les droits exclusifs de distribution mondiale sur le marché de la santé animale.
La première expédition commerciale est prévue pour le troisième trimestre 2025. ALRT prévoit d’établir une coentreprise avec CGM Medical afin de construire une usine de fabrication automatisée à Singapour, sous réserve de la réussite des tests d’échantillons et des seuils de production. L’entreprise vise à étendre sa présence sur les marchés du diabète humain et animal, en envisageant des opportunités d’investissement et commerciales.
ALR Technologies (OTCPK:ALRTF) hat eine endgültige Fertigungsvereinbarung mit CGM Medical Technology Shen Zhen für die Produktion der Hardware des kontinuierlichen Glukosemonitors (CGM) für sein GluCurve Pet CGM-System abgeschlossen. Die Vereinbarung gewährt ALRT exklusive weltweite Vertriebsrechte im Tiergesundheitsmarkt.
Die erste kommerzielle Lieferung wird im dritten Quartal 2025 erwartet. ALRT plant, gemeinsam mit CGM Medical ein automatisiertes Fertigungswerk in Singapur zu errichten, vorbehaltlich erfolgreicher Musterprüfungen und Produktionsschwellen. Das Unternehmen beabsichtigt, seine Präsenz in den Diabetesmärkten für Mensch und Tier auszubauen und prüft mögliche Investitionen und kommerzielle Chancen.
- Secured exclusive global distribution rights for animal health market
- First commercial shipment expected in Q3 2025
- Plans for automated manufacturing facility in Singapore to improve efficiency and reduce costs
- Potential investment and commercial opportunities in human health initiatives
- Manufacturing agreement subject to CGM hardware meeting ALRT specifications
- Production facility plans contingent on successful sample testing and production thresholds
"We have been collaborating with CGM Medical to develop the first large scale manufacturing line for the CGM units that will be part of the ALRT GluCurve Pet CGM," comments Mr. Sidney Chan, Chairman and CEO of ALR Technologies SG Ltd. "When sample testing and adjustments are complete and production thresholds are met, we plan to enter into a joint venture agreement with CGM Medical to build a larger, fully automated manufacturing facility in
Mr. Chan continues "completing this Manufacturing Agreement is the first step in our long-term plan to make ALR Technologies a fully integrated player in the diabetes market by having a vested interest in CGM manufacturing in addition to our product offerings and platforms for human and animal health. We have been diligently working on our human health initiatives and have received interest from third parties for both investment and commercial opportunities which we hope to advance this year."
The Definitive Manufacturing Agreement is subject to certain conditions including the performance of the CGM hardware units meeting ALRT specifications.
About CGM Medical Technology Shen Zhen Ltd
CGM Medical is an innovative medical device technology company that provides technical services, software and technical development, technology transfer, artificial intelligence industry application and engineering and technical research. Its key focus is developing an accurate and affordable continuous glucose monitoring device for diabetic patients.
The management and technical team are experienced in leading corporate, governmental and professional organizations in the areas of continuous glucose monitoring research and manufacturing factory automation, life sciences, chemical and material engineering, innovation and data security. Their core team has collectively overseen numerous national science and technology projects and filing of multiple patents and software copyrights.
About ALR Technologies SG Ltd.
ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes.
In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans.
More information about ALRT and the GluCurve Pet CGM can be found at www.alrt.com and www.GluCurve.com in the
Investor Contact
Investor Relations: ir@alrt.com
Animal Health Inquiries: animalhealth@alrt.com
Media: Media@alrt.com
US: +1 804 554 3500
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This news release includes certain "forward-looking statements" as defined under applicable securities legislation. All information and statements contained herein that are not clearly historical in nature constitute forward-looking statements and information, and the words "anticipate", "estimate", "believe", "continue", "could", "expect", "intend", "plan", "postulates", "predict", "will", "may" or similar expressions suggesting future conditions or events, or the negative of these terms, are generally intended to identify forward-looking information. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks include all risks and uncertainties expressed in the cautionary statements and risk factors in the annual report on Form 20-F and other filings of ALRT with the SEC. The forward-looking statements included in this news release are made as of the date hereof. Forward-looking statements include representations to the effect that the Company will receive satisfactory CGM samples from CGM Medical, that the Company will enter into a joint venture agreement with CGM Medical and that if a joint venture agreement is entered into, that it will result in increased performance and reduced costs for CGM units produced. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. ALRT disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View original content:https://www.prnewswire.com/news-releases/alr-technologies-completes-definitive-manufacturing-agreement-for-glucurve-pet-cgm-302490638.html
SOURCE ALR Technologies SG Ltd.
FAQ
What is the significance of ALRTF's manufacturing agreement with CGM Medical?
When will ALRTF receive its first commercial shipment of GluCurve Pet CGMs?
What are ALRTF's future manufacturing plans for the GluCurve Pet CGM?
What conditions must be met for ALRTF's manufacturing agreement?
What are ALRTF's expansion plans in the diabetes market?
